Welcome to our dedicated page for UNITED THERAPEUTICS SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
United Therapeutics Corp Chairperson and CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On March 12, 2026, she exercised 9,500 stock options at an exercise price of $146.03 per share, receiving 9,500 shares of common stock.
That same day and on March 16, 2026, she completed open-market sales totaling 9,500 common shares at weighted average prices generally between $531.94 and $544.80. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
Following these trades, Rothblatt holds 8,414 shares of common stock directly. She also has indirect interests, including 166 shares held by her spouse and shares held in various family trusts, such as 324,518 shares in one trust where family members are beneficiaries.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options covering 9,500 shares of common stock at an exercise price of $146.03 per share and acquired the same number of shares. On the same March 11, 2026, she sold 9,500 common shares in multiple open‑market transactions at prices ranging from $531.90 to $544.94, leaving 130 shares held directly.
The options exercised were originally granted on March 15, 2020 and were scheduled to expire on March 15, 2027. The filing also shows additional indirect holdings, including shares held by a spouse and in several family trusts, such as 324,518 and 258,117 shares reported as held by trusts. All option exercises and related sales were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025, which is set to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
United Therapeutics Corp Chairperson and CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share, then sold 9,500 shares in multiple open-market trades at prices generally between about $530 and $548 per share. These transactions on March 10, 2026 were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is designed to execute trades automatically over time. Following the sales, she holds 130 shares directly and also has substantial indirect holdings through family trusts, including 324,518 shares held by a trust.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On March 9, 2026, she exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and received 9,500 shares.
That same day, she sold 9,500 shares of common stock in a series of open-market trades, including 200 shares at $500.05 per share and 80 shares at $529.83 per share. After these trades, she held 130 shares directly, and also reported additional indirect holdings through her spouse and several family trusts.
The footnotes state that this option exercise and sale of resulting shares were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share on March 6, 2026. She then sold 9,500 shares in multiple open-market transactions at prices reported between $471.96 and $484.27 per share.
The filing notes these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which runs until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026. Following the sales, she holds 130 shares directly and additional indirect holdings through her spouse and family trusts.
United Therapeutics Corporation authorized a new stock repurchase program of up to $2.0 billion of common stock to be executed before March 9, 2027. To launch the program, the company entered into two accelerated share repurchase agreements with Citi totaling $1.5 billion, split between a $750 million uncollared ASR and a $750 million collared ASR.
The company will make an upfront payment of $1.5 billion on or around March 11, 2026 and expects initial delivery of approximately 992,120 shares under the uncollared ASR and approximately 708,657 shares under the collared ASR. Final shares repurchased will depend on the average daily volume-weighted average price over each ASR term, with the uncollared ASR scheduled to end in the second quarter of 2026 and the collared ASR in the third quarter of 2026. An additional $500 million remains authorized for future repurchases over the next year at the company’s discretion.
UNITED THERAPEUTICS Corp director Judy D. Olian sold common stock in a planned transaction. On March 6, 2026, she completed an open-market sale of 200 shares of common stock at a price of $510 per share, leaving her with 4,645 shares held directly.
According to a footnote, this sale was made under a pre-arranged Rule 10b5-1 trading plan that she entered into on November 24, 2025. Such plans are designed to allow insiders to systematically sell shares over time according to predetermined instructions.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares on March 5, 2026, converting derivative securities into common stock at a reported exercise price of $146.03 per share.
On the same date, she sold a total of 9,500 common shares in a series of open-market transactions, with reported weighted-average prices ranging from $479.8871 to $487.9813, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she directly held 130 common shares, in addition to indirect holdings reported as 166 shares by spouse and 324,518, 258,117, 45,596 and 10,962 shares held by various family trusts.
Judy Olian reported the sale of 200 common shares. The Form 144 shows 200 restricted shares granted 06/26/2021 and sold on 03/02/2026 for $101,910.00. The filer is listed as Morgan Stanley Smith Barney LLC.
UNITED THERAPEUTICS Corp executive Paul A. Mahon, EVP & General Counsel, reported exercising stock options and selling resulting shares. On March 5, 2026, he exercised 8,300 stock options at a reported price of $0.0000 per option, receiving 8,300 shares of common stock at a reported price of $146.0300 per share.
The filing shows multiple open-market sales totaling 8,300 shares of common stock on the same date at reported weighted average prices between about $479.4271 and $487.6520. A footnote states these option exercises and related sales were made under a pre-arranged 10b5-1 trading plan entered into on August 11, 2025. After these transactions, Mahon directly held 36,844 shares of common stock and 33,500 stock options as of March 5, 2026, including 63 shares acquired on March 4, 2026 under the United Therapeutics Employee Stock Purchase Plan.